At a glance
| Length | 10 amino acids |
|---|---|
| Target | KISS1R / GPR54 |
| Pathway | Upstream stimulation of GnRH |
| Human evidence | Small endocrine-physiology studies |
| Approved US indication | None identified |
| Common evidence error | Substituting kisspeptin-54 studies |
Overview
Kisspeptin-10 is the active ten-amino-acid end of the kisspeptin family encoded by KISS1. It acts upstream of GnRH and is useful for studying how the brain regulates reproduction. Human research includes brief controlled exposure in healthy men and a small study in men with type 2 diabetes and mild biochemical hypogonadism. These studies examine hormone secretion rather than long-term clinical outcomes. The wider kisspeptin literature also includes kisspeptin-54 and other analogues, which must not be treated as interchangeable evidence for this exact fragment or for products sold outside clinical research.
How it works
Kisspeptin-10 activates KISS1R, historically called GPR54, on the reproductive neuroendocrine pathway. This can stimulate GnRH secretion and subsequently pituitary LH and FSH release, with downstream effects on gonadal hormone production. Response depends on exposure pattern and the physiological state of the axis. A short-lived rise in LH demonstrates biological activity but does not by itself establish sustained improvement in fertility, symptoms or sexual function.
What has kisspeptin-10 shown in people?
A controlled study in healthy men demonstrated increased LH secretion and changes in LH pulsatility during intravenous kisspeptin-10 exposure. A separate small study in men with type 2 diabetes and mild biochemical hypogonadism showed LH and testosterone responses. Neither establishes durable symptom improvement or a fertility treatment.
Are sexual-desire trials evidence for this fragment?
Some frequently cited sexual-processing and desire studies administered kisspeptin-54. For example, a randomized study in women with hypoactive sexual desire disorder used that longer peptide. Such results can inform the broader pathway but should not be relabeled as trials of kisspeptin-10.
Supporting sources [3]
What is known about safety and product quality?
FDA identifies potential immunogenicity, peptide-impurity and active-ingredient-characterization concerns for compounded kisspeptin-10. Available safety information for proposed administration routes is inadequate. Short research exposures cannot establish the safety of repeated use, different routes, pregnancy exposure or products with uncertain identity and purity.
Supporting sources [4]
Does a rise in LH mean fertility has improved?
No. Hormone secretion is an intermediate biological measurement. Fertility depends on many additional factors, and meaningful evidence would include outcomes such as sperm production, ovulation or live birth in appropriate populations. Kisspeptin-10 remains investigational rather than an FDA-approved fertility or libido medicine.
Reading this profile
Jurisdiction: No FDA-approved kisspeptin-10 medicine; small human research studies do not establish approved clinical use.. Molecular class: Ten-amino-acid kisspeptin fragment and KISS1 receptor agonist.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men ↗Original research · Checked 2026-10-27
- Kisspeptin-10 stimulates LH and testosterone in men with type 2 diabetes and mild biochemical hypogonadism ↗Original research · Checked 2026-10-27
- Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. ↗Original research · Checked 2026-10-27
- FDA — bulk substances with potential significant safety risks ↗Regulatory source · Checked 2026-10-27